PTPI Petros Pharmaceuticals Inc

6,469

$1.38

$0.07

(5.34%)

Today

Market Cap	$2.88M
Volume (M)	128,689.00
52-Wk High	$9.54
52-Wk Low	$0.9172

ST Data

Watchers

New Watcher Rank

Fundamentals

Petros Pharmaceuticals partners with Idea EvolverThe Fly • 4 days ago

See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Share to Feed

Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor's (rosuvastatin) OTC Switch Technology ProviderAccesswire • 4 days ago

Idea Evolver is the only provider to successfully complete Actual Use Trial for FDA review for Rx-to-OTC Switch ApprovalNEW YORK, NY / ACCESSWIRE / December 5, 2023 / Petros Pharmaceuticals, Inc...

Petros Pharmaceuticals Petros Pharmaceuticals Developing Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R)Accesswire • about 1 month ago

New AI/machine learning tool designed to help potential users more effectively self-select in the effort to make STENDRA the first erectile dysfunction (ED) medication available OTCPetros in...

Following Encouraging FDA Feedback Petros Pharmaceuticals Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRAAccesswire • about 2 months ago

Important step towards STENDRA potentially becoming the first erectile dysfunction medication to successfully achieve OTC StatusNEW YORK, NY / ACCESSWIRE / October 19, 2023 / Petros Pharmaceuticals...

Petros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential OTC STENDRA LabelAccesswire • 2 months ago

Company well positioned to continue collaboration with FDA toward pursuit of OTC pathway for STENDRANEW YORK, NY / ACCESSWIRE / October 4, 2023 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company...

Petros Pharmaceuticals Provides Letter to ShareholdersAccesswire • 3 months ago

NEW YORK, NY / ACCESSWIRE / September 11, 2023 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over the counter (OTC) pathway...

Petros Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAccesswire • 3 months ago

NEW YORK, NY / ACCESSWIRE / September 6, 2023 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a pioneer in expanding consumer access to medication through over the counter (OTC) pathways, announces...

Petros Pharmaceuticals slips on $15M private placement financingSeekingAlpha.com: All News • 5 months ago

Petros Pharmaceuticals Announces Capital Raise of $15 MillionAccesswire • 5 months ago

Provides Update on Progress Toward Over the Counter (non-prescription) Development of STENDRANEW YORK, NY / ACCESSWIRE / July 13, 2023 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ('Petros' or 'the Company'), a pioneer in expanding consumer access to medication through the over...

Petros Pharmaceuticals (NASDAQ:PTPI) Stock Price Down 1.1%Zolmax • 5 months ago

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI Free Report)s stock price traded down 1.1% on Friday . The stock traded as low as $1.80 and last traded at $1.81. 8,840 shares changed hands during trading, a decline of 99% from the average session volume of 1,299,432 shares. The stock had previously closed...